Insmed

Insmed Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Insmed (INSM) as of Nov 2, 2026 is 0.90. In the previous year, Net Debt to Free Cash Flow Ratio was 0.20 — a change of 345.72% (higher).

Net Debt/FCF

0.90

YoY

345.72%

Last updated:

Net Debt to Free Cash Flow Ratio of Insmed is 2025 0.90 . Net Debt to Free Cash Flow Ratio of Insmed was 2024 0.20 . It decreases by 345.72% higher compared to the previous year.

The Insmed Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
0.65 USD
Jan 1, 2019
0.45 USD
Jan 1, 2020
0.71 USD
Jan 1, 2021
0.37 USD
Jan 1, 2022
-0.02 USD
Jan 1, 2023
-1.02 USD
Jan 1, 2024
0.20 USD
Jan 1, 2025
0.90 USD
The Insmed Net Debt/FCF history
YEARNet Debt/FCFYoY
0.90+345.72%
0.20-119.81%
-1.02+5,242.51%
-0.02-105.21%
0.37-48.53%
0.71+59.16%
0.45-31.78%
0.65-67.32%
2.00+180.28%
0.71-71.14%
2.47+28.55%
1.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Insmed Stock analysis

What does Insmed do? Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insmed stock

Net Debt to Free Cash Flow Ratio of Insmed is 0.90 in 2025.

Net Debt to Free Cash Flow Ratio of Insmed changed from 0.20 to 0.90, representing a 345.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Insmed since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Insmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Insmed

All Key Metrics — Insmed